DK3425390T3 - Sammensætning til fremme af differentiering og beskyttelse af neurale stamceller og fremgangsmåde til induktion af neural regenerering ved anvendelse heraf - Google Patents

Sammensætning til fremme af differentiering og beskyttelse af neurale stamceller og fremgangsmåde til induktion af neural regenerering ved anvendelse heraf Download PDF

Info

Publication number
DK3425390T3
DK3425390T3 DK17874605.3T DK17874605T DK3425390T3 DK 3425390 T3 DK3425390 T3 DK 3425390T3 DK 17874605 T DK17874605 T DK 17874605T DK 3425390 T3 DK3425390 T3 DK 3425390T3
Authority
DK
Denmark
Prior art keywords
protection
composition
stem cells
neural
promoting differentiation
Prior art date
Application number
DK17874605.3T
Other languages
English (en)
Inventor
Kang-Yell Choi
Mi-Yeon Kim
Sungho Han
Original Assignee
Genuv Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genuv Inc filed Critical Genuv Inc
Application granted granted Critical
Publication of DK3425390T3 publication Critical patent/DK3425390T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/4833—Physical analysis of biological material of solid biological material, e.g. tissue samples, cell cultures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5026—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on cell morphology
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases (EC 2.)
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/08—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from cells of the nervous system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
DK17874605.3T 2016-11-25 2017-11-23 Sammensætning til fremme af differentiering og beskyttelse af neurale stamceller og fremgangsmåde til induktion af neural regenerering ved anvendelse heraf DK3425390T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20160158739 2016-11-25
KR20170036268 2017-03-22
PCT/KR2017/013444 WO2018097628A2 (ko) 2016-11-25 2017-11-23 신경줄기세포의 분화 촉진 및 보호용 조성물 및 이를 이용하여 신경재생을 유도하는 방법

Publications (1)

Publication Number Publication Date
DK3425390T3 true DK3425390T3 (da) 2021-02-15

Family

ID=62196019

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17874605.3T DK3425390T3 (da) 2016-11-25 2017-11-23 Sammensætning til fremme af differentiering og beskyttelse af neurale stamceller og fremgangsmåde til induktion af neural regenerering ved anvendelse heraf

Country Status (20)

Country Link
US (3) US10485802B2 (da)
EP (2) EP3800471A1 (da)
JP (2) JP6663509B2 (da)
KR (4) KR101892457B1 (da)
CN (2) CN115025225A (da)
AU (1) AU2017363804B2 (da)
BR (1) BR112019009711A2 (da)
CA (1) CA3041245C (da)
CL (1) CL2019001415A1 (da)
DK (1) DK3425390T3 (da)
ES (1) ES2848720T3 (da)
HU (1) HUE052854T2 (da)
IL (1) IL266573B (da)
MX (1) MX2019006040A (da)
MY (1) MY194462A (da)
NZ (1) NZ754020A (da)
PH (1) PH12019501143A1 (da)
SG (2) SG10202105383QA (da)
WO (1) WO2018097628A2 (da)
ZA (1) ZA201903226B (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3800471A1 (en) 2016-11-25 2021-04-07 Genuv Inc. Composition for promoting differentiation of and protecting neural stem cells and method for inducing neural regeneration using same
EP3962514A4 (en) * 2019-05-02 2023-04-19 Board of Regents, The University of Texas System METHODS AND COMPOSITIONS INVOLVING TERT ACTIVATION THERAPIES
KR20220024161A (ko) * 2019-05-22 2022-03-03 주식회사 지뉴브 트라메티닙 및 마커를 이용한 신경퇴행성 질환의 치료를 위한 투여 방법 및 투약 용법
CN111143763B (zh) * 2019-12-13 2021-09-17 广东电网有限责任公司 电力设备状态的评估方法、装置及其存储介质
KR20230004597A (ko) * 2020-04-14 2023-01-06 주식회사 지뉴브 신경퇴행성질환 치료제에 대한 반응을 평가하기 위한 방법 및 조성물
WO2022045723A1 (ko) * 2020-08-24 2022-03-03 차의과학대학교 산학협력단 신경줄기세포의 도파민 신경세포로의 분화 촉진용 조성물
CN112695019B (zh) * 2021-03-23 2021-06-25 翌圣生物科技（上海）有限公司 逆转录酶突变体及其应用
CN115322966B (zh) * 2022-08-19 2024-04-16 山东大学 叶酸钙纳米颗粒的批量制备方法及诱导神经干细胞分化为胆碱能神经元的方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6310060B1 (en) * 1998-06-24 2001-10-30 Warner-Lambert Company 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
CZ2003680A3 (cs) * 2000-08-11 2003-11-12 Cephalon, Inc. Způsob modulace kinasových proteinů s vícenásobnou vazbou a vyhledávání sloučenin modulujících kinasové proteiny s vícenásobnou vazbou
MXPA04010255A (es) * 2002-04-19 2008-03-04 Univ Toronto Metodos inmunologicos y composiciones para el tratamiento de la enfermedad de alzheimier.
AU2003252559A1 (en) 2002-08-17 2004-03-03 Hae-Young Suh A method for transdifferentiating mesenchymal stem cells into neuronal cells
RS52670B (en) 2004-06-11 2013-06-28 Japan Tobacco Inc. 5-AMINO-2,4,7-TRIOXO-3,4,7,8-TETRAHYDRO-2H-PIRIDO (2,3-D) PYRIMIDINE DERIVATIVES AND SIMILAR COMPOUNDS FOR CANCER TREATMENT
CN101076543A (zh) * 2004-10-13 2007-11-21 阿布林克斯公司 用于治疗和诊断变性神经疾病如阿尔茨海默症的单结构域骆驼抗淀粉样蛋白β的抗体以及包含它的多肽
KR101318012B1 (ko) 2004-10-20 2013-10-14 메르크 세로노 에스.에이. 3-아릴아미노 피리딘 유도체
WO2006061717A2 (en) * 2004-12-09 2006-06-15 Neuro Therapeutics Ab Materials and methods related to dickkopfs (dkk) and neurogenesis
JP4792290B2 (ja) * 2005-12-27 2011-10-12 財団法人 東京都医学総合研究所 神経幹細胞の製造方法
FR2905009A1 (fr) * 2006-08-18 2008-02-22 Servier Lab Methode de criblage de composes aux proprietes anti-amyloide
KR101082484B1 (ko) * 2007-11-06 2011-11-11 한국과학기술원 퇴행성 신경질환 치료제의 스크리닝 방법
KR20100088342A (ko) * 2009-01-30 2010-08-09 연세대학교 산학협력단 신경줄기세포의 분화 촉진용 조성물
WO2010137547A1 (ja) * 2009-05-25 2010-12-02 国立大学法人東京工業大学 中枢神経細胞の増殖及び分化に係る中核因子を含む医薬組成物
EP2435585A4 (en) * 2009-05-28 2013-02-20 Univ Central Florida Res Found METHOD FOR SCREENING MEDICAMENTS FOR INVERSION OF NEUROTOXICITY OF BETA AMYLOID
WO2011062013A1 (ja) * 2009-11-18 2011-05-26 国立大学法人徳島大学 神経幹細胞及び／又は神経系前駆細胞への選択的分化誘導剤
KR101211610B1 (ko) 2010-05-10 2012-12-12 주식회사 스템폰즈 Ｂｍｉ１, ＭＥＫ 억제제와 ＧＳＫ 억제제를 이용하여 체세포로부터 배아줄기세포 유사세포로의 역분화를 유도하는 조성물 및 이를 이용한 배아줄기세포 유사세포의 제조방법
KR102029391B1 (ko) * 2011-12-13 2019-11-08 유니사 벤쳐스 피티와이 엘티디 다능성 줄기세포의 제조방법
ES2415581B2 (es) 2011-12-20 2014-02-19 Universidad Nacional De Educación A Distancia Compuestos potenciadores del aprendizaje.
US9452215B2 (en) * 2012-02-22 2016-09-27 The Regents Of The University Of Colorado Bourvadin derivatives and therapeutic uses thereof
CN102604894B (zh) * 2012-02-29 2014-07-30 中国科学院广州生物医药与健康研究院 用于制备神经干细胞的培养基及其用途
HUE028850T2 (en) 2012-05-30 2017-01-30 Merck Patent Gmbh N-((S) -2,3-Dihydroxypropyl) -3- (2-fluoro-4-iodo-phenylamino) -isonicotinamide solid forms
US10017734B2 (en) 2013-08-06 2018-07-10 Takeda Pharmaceutical Company Limited Method for producing dopaminergic neurons
US9532987B2 (en) * 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
US9943549B2 (en) * 2015-03-17 2018-04-17 Food Industry Research And Development Institute Isolation of human neural stem cells from amniotic fluid of patients with neural tube defects
KR20160138756A (ko) 2015-05-26 2016-12-06 연세대학교 산학협력단 신경줄기세포로부터 도파민 신경세포로의 분화 유도용 조성물 및 이를 이용하여 신경줄기세포로부터 도파민 신경세포로 분화시키는 방법
US10179132B2 (en) 2015-05-26 2019-01-15 Industry-Academic Cooperation Foundation, Yonsei University Composition for inducing differentiation of multipotent neural stem cells into dopaminergic neurons and method for inducing differentiation of multipotent neural stem cells into dopaminergic neurons by using the same
WO2017117386A1 (en) 2015-12-30 2017-07-06 Icahn School Of Medicine At Mount Sinai Methods of treating cancer using network brakes
WO2017161188A1 (en) 2016-03-16 2017-09-21 The Regents Of The University Of California Detection and treatment of anti-pd-1 therapy resistant metastatic melanomas
CN109715802A (zh) 2016-03-18 2019-05-03 卡里斯科学公司 寡核苷酸探针及其用途
EP3240538B1 (en) 2016-03-25 2021-09-29 AB Science Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation
CN105816461B (zh) 2016-04-06 2018-10-30 福州大学 曲美替尼在制备治疗帕金森症药物上的应用
CN105796544A (zh) * 2016-04-06 2016-07-27 福州大学 Mapk信号通路抑制剂在制备治疗帕金森药物上的应用
JP2019521116A (ja) 2016-06-07 2019-07-25 センター フォー セルラー アンド モレキュラー プラットフォームズ 神経炎症及び神経変性を管理するための方法及び組成物
EP3800471A1 (en) 2016-11-25 2021-04-07 Genuv Inc. Composition for promoting differentiation of and protecting neural stem cells and method for inducing neural regeneration using same
WO2018225062A1 (en) 2017-06-04 2018-12-13 Rappaport Family Institute For Research In The Medical Sciences Method of predicting personalized response to cancer therapy and kit therefor

Also Published As

Publication number Publication date
KR102519796B1 (ko) 2023-04-11
MX2019006040A (es) 2019-08-21
US20180169102A1 (en) 2018-06-21
CA3041245A1 (en) 2018-05-31
US11147816B2 (en) 2021-10-19
US10485802B2 (en) 2019-11-26
AU2017363804B2 (en) 2021-12-23
WO2018097628A2 (ko) 2018-05-31
CN109073634B (zh) 2022-07-08
HUE052854T2 (hu) 2021-05-28
BR112019009711A2 (pt) 2019-08-13
NZ754020A (en) 2022-11-25
EP3800471A1 (en) 2021-04-07
MY194462A (en) 2022-11-30
KR20180116235A (ko) 2018-10-24
PH12019501143A1 (en) 2019-12-16
JP2019513806A (ja) 2019-05-30
WO2018097628A3 (ko) 2018-08-09
IL266573B (en) 2022-03-01
IL266573A (en) 2019-07-31
AU2017363804A1 (en) 2019-06-20
KR20200056465A (ko) 2020-05-22
CL2019001415A1 (es) 2019-10-04
EP3425390A4 (en) 2019-12-25
ES2848720T3 (es) 2021-08-11
KR102114017B1 (ko) 2020-05-22
ZA201903226B (en) 2023-12-20
JP2020074796A (ja) 2020-05-21
EP3425390A2 (en) 2019-01-09
KR20210095748A (ko) 2021-08-02
US20210401844A1 (en) 2021-12-30
CA3041245C (en) 2022-12-06
SG10202105383QA (en) 2021-07-29
EP3425390B1 (en) 2020-12-23
US20200046706A1 (en) 2020-02-13
JP6663509B2 (ja) 2020-03-11
KR101892457B1 (ko) 2018-08-31
CN115025225A (zh) 2022-09-09
CN109073634A (zh) 2018-12-21
SG11201903725UA (en) 2019-05-30
US11701360B2 (en) 2023-07-18

Similar Documents

Publication Publication Date Title
DK3425390T3 (da) Sammensætning til fremme af differentiering og beskyttelse af neurale stamceller og fremgangsmåde til induktion af neural regenerering ved anvendelse heraf
DK3206493T3 (da) Sammensætninger og fremgangsmåder til behandling af cns-forstyrrelser
DK3221457T3 (da) Fremgangsmåder og sammensætninger til targeteret genomisk modifikation ved anvendelse af parrede førings-rnaer
DK3500664T3 (da) Fremgangsmåde til differentiering af pluripotente celler
DK3328285T3 (da) Fremgangsmåde og system til korrigering af fedt-inducerede aberrationer
DK3402483T3 (da) Fremgangsmåder og sammensætninger til aktivering af gamma-delta-T-celler
DK3218320T3 (da) Fremgangsmåde til varmebehandling af naturligt ler og/eller zeoliter
DK3250210T3 (da) Sammensætninger og fremgangsmåder til behandling af cns-forstyrrelser
DE112016004932T8 (de) System, Verfahren und Cloud-basierte Plattform zur Vorhersage des Energieverbrauchs
DK3353168T3 (da) Forbindelser og fremgangsmåder til at inhibere jak
DK3467904T3 (da) Separator med høj vådbarhed og fremgangsmåde til fremstilling deraf
HK1247705A1 (zh) 用於應用預測性社交評分來執行重點風險評估的系統和方法
DK3253412T3 (da) Anti-cd40l-antistoffer og fremgangsmåder til behandling af cd40l-forbundne sygdomme eller forstyrrelser
DK3233071T3 (da) Fremgangsmåde til behandling eller forebyggelse af Ras-medierede sygdomme
DK3110446T3 (da) Fremgangsmåder og sammensætninger til behandling af Siglec-8-associerede sygdomme
DK3475637T3 (da) Anlæg og fremgangsmåde til termisk behandling af luftbåret råmateriale
DK3242947T3 (da) Genterapi og elektroporese til behandling af maligniteter
DK3390367T3 (da) Fremgangsmåde til forebyggelse og/eller behandling af aldersrelateret kognitiv funktionsnedsættelse og neuroinflammation
DK3606467T3 (da) Proteseklapper og fremgangsmåder til deres fremstilling
DK3402575T3 (da) Fremgangsmåder og sammensætninger til behandling af beskadiget hår
DK3268315T3 (da) System og fremgangsmåde til behandling af fluider ved hjælp af sonoelektrokemi
DK3253766T3 (da) Forbindelser og fremgangsmåder til forebyggelse eller behandling af sansehårscelledød
DK3185992T3 (da) Fremgangsmåde og system til opsamling af CO2 ved hjælp af Thermovibrio ammonificans-kulsyreanhydrase
DK3186240T3 (da) Heterobicykliske forbindelser og deres anvendelse til behandling af tuberkulose
DK3389620T3 (da) Stamcellestimulerende sammensætninger og fremgangsmåder til behandling af melasma